Page last updated: 2024-08-05 11:02:03
phenanthridines
Any dibenzopyridine based on the skeleton of phenanthridine and its substituted derivatives thereof.
ChEBI ID: 51245
Members (16)
Member | Definition | Role |
---|---|---|
2-[(2,3-dimethyl-7,8,9,10-tetrahydrophenanthridin-6-yl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide | 2-[(2,3-dimethyl-7,8,9,10-tetrahydrophenanthridin-6-yl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide | |
5H-phenanthridine-6-thione | 5H-phenanthridine-6-thione | |
7-deoxypancratistatin | 7-Deoxypancratistatin | |
anhydrolycorinone | Anhydrolycorinone | |
cy 208-243 | LSM-3788 | |
dihydrexidine | (6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol | |
ethidium | The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA. | ethidium |
lycoricidine | Lycoricidine | |
narciclasine | Narciclasine | |
nitidine | Nitidine | |
phenanthridine | An azaarene that is the 9-aza derivative of phenanthrene. The parent of the class of phenanthridines. | phenanthridine |
phenanthridone | A member of the class of phenanthridines that is phenanthridine with an oxo substituent at position 6. A poly(ADP-ribose) polymerase (PARP) inhibitor, it has been shown to exhibit immunosuppressive activity. | phenanthridone |
pj-34 | A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | PJ34 |
propidium | propidium | |
pseudolycorine | Pseudolycorine | |
trispheridine | Trisphaeridine |
Research
Studies (7,763)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 1,968 (25.35) | 18.7374 |
1990's | 1,519 (19.57) | 18.2507 |
2000's | 2,263 (29.15) | 29.6817 |
2010's | 1,706 (21.98) | 24.3611 |
2020's | 307 (3.95) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 28 (0.34%) | 5.53% |
Reviews | 112 (1.37%) | 6.00% |
Case Studies | 12 (0.15%) | 4.05% |
Observational | 2 (0.02%) | 0.25% |
Other | 8,025 (98.12%) | 84.16% |